BioAtla, Inc. (BCAB)
NASDAQ: BCAB · Real-Time Price · USD
0.4563
+0.0756 (19.86%)
At close: Apr 24, 2025, 4:00 PM
0.4600
+0.0037 (0.81%)
Pre-market: Apr 25, 2025, 5:40 AM EDT
BioAtla Employees
BioAtla had 61 employees as of December 31, 2024. The number of employees decreased by 4 or -6.15% compared to the previous year.
Employees
61
Change (1Y)
-4
Growth (1Y)
-6.15%
Revenue / Employee
$180,328
Profits / Employee
-$1,143,869
Market Cap
26.65M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 61 | -4 | -6.15% |
Dec 31, 2023 | 65 | -1 | -1.52% |
Dec 31, 2022 | 66 | 10 | 17.86% |
Dec 31, 2021 | 56 | 20 | 55.56% |
Dec 31, 2020 | 36 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
BCAB News
- 21 hours ago - BioAtla Announces Poster Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting - GlobeNewsWire
- 1 day ago - BioAtla Announces Upcoming Poster Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - GlobeNewsWire
- 4 weeks ago - BioAtla, Inc. (BCAB) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - BioAtla Cuts 30% of Jobs in Restructuring Effort - Market Watch
- 4 weeks ago - BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress - GlobeNewsWire
- 5 weeks ago - BioAtla Announces Two Poster Presentations at Upcoming Medical Meetings - GlobeNewsWire
- 5 weeks ago - BioAtla to Announce Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Highlights on March 27, 2025 - GlobeNewsWire
- 7 weeks ago - AXL Inhibitors Pipeline Research Report 2025: Features Insights on 16+ Companies and 20+ Pipeline Drugs, Including Cabozantinib (Exelixis/Ipsen), BA 3011 (BioAtla) & TP-0903 (Sumitomo Dainippon Pharma Oncology) - GlobeNewsWire